Q3 2024 Earnings Call Transcript November 7, 2024 Skye Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.25. Operator: Ladies and gentlemen, thank you for ...

"The GLP1s are relatively new and are being rolled-out as scale. We have no idea what damage 20 years of drug-induced ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

Hanmi Pharm. Co., Ltd. has announced promising research results for its novel obesity treatment, HM17321. This groundbreaking ...

What is ageing? Ageing is a highly complex biological process. Our DNA is constantly being broken down and repaired. An ...

Amid the rise of gut health and GLP-1 drugs in the UK, Potina is making high-fibre banana oat milks for improved children's ...

“A leading public health priority, obesity and diabetes cumulatively impact more than one billion individuals worldwide. While the emergence of incretin-based medicines has provided new treatment ...

CRB-913 brain levels are 15-fold lower than monlunabant in lean miceDose-response demonstrated for a range of 5 to 80 ...

The stock, which enjoys the unusual position of having all buy ratings from the 13 analysts offering coverage on FactSet, has been on a tear this year, gaining 270% to date in 2024.